Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jaguar Health, Inc.JAGX · Entity 8387 | CFO and Treasurer | July 24, 2019 | July 26, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jaguar Health, Inc.
Report date July 24, 2019 · Filed July 26, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.73 · Expires 2022-07-24 | Direct | 303,932 |
Reported balance
After 2019-07-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-07-24 · Grant · Acquired 303,932 · Balance 303,932 F1: Granted pursuant to the issuer's 2014 Equity Incentive Plan. F2: The option grant was approved by the issuer's board of directors on July 19, 2019, subject to James J. Bochnowski, the chairman of the board of directors, and the reporting person, in her capacity as the Chief Financial Officer of the issuer, determining the exact number of option shares to be granted per option based on the issuer's fully diluted shares outstanding following the issuer's underwritten public offering that closed on July 23, 2019. Mr. Bochnowski and the reporting person certified the exact number of option shares to be granted on July 24, 2019, such that the effective date of the option grant was July 24, 2019. F3: Vests in equal monthly installments beginning on July 24, 2019, with four months of options, or 33,770 options, vested as of the grant date based on the reporting person's number of years of employment with the issuer, such that the grant is vested in full on the 3-year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Granted pursuant to the issuer's 2014 Equity Incentive Plan.
F2: The option grant was approved by the issuer's board of directors on July 19, 2019, subject to James J. Bochnowski, the chairman of the board of directors, and the reporting person, in her capacity as the Chief Financial Officer of the issuer, determining the exact number of option shares to be granted per option based on the issuer's fully diluted shares outstanding following the issuer's underwritten public offering that closed on July 23, 2019. Mr. Bochnowski and the reporting person certified the exact number of option shares to be granted on July 24, 2019, such that the effective date of the option grant was July 24, 2019.
F3: Vests in equal monthly installments beginning on July 24, 2019, with four months of options, or 33,770 options, vested as of the grant date based on the reporting person's number of years of employment with the issuer, such that the grant is vested in full on the 3-year anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 24, 2019 Filed Jul 26, 2019 16:48 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantStock Option (right to buy) · Derivative | 303,932 | $0.00 Strike: $1.73 | $0.00 |
DisclosureSEC source: 0001104659-19-042082 · a4.xml · derivative · entry 1 Wright Karen Steil · CIK 0001310280 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,932 Underlying: Common Stock · 303,932 shares Expires 2022-07-24 F1 · security: Granted pursuant to the issuer's 2014 Equity Incentive Plan. F2 · date: The option grant was approved by the issuer's board of directors on July 19, 2019, subject to James J. Bochnowski, the chairman of the board of directors, and the reporting person, in her capacity as the Chief Financial Officer of the issuer, determining the exact number of option shares to be granted per option based on the issuer's fully diluted shares outstanding following the issuer's underwritten public offering that closed on July 23, 2019. Mr. Bochnowski and the reporting person certified the exact number of option shares to be granted on July 24, 2019, such that the effective date of the option grant was July 24, 2019. F3 · derivative.exercise_date: Vests in equal monthly installments beginning on July 24, 2019, with four months of options, or 33,770 options, vested as of the grant date based on the reporting person's number of years of employment with the issuer, such that the grant is vested in full on the 3-year anniversary of the grant date. Read SEC document |
| June 01, 2018 Filed Jun 6, 2018 21:28 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantStock Option (right to buy) · Derivative | 85,854 | $0.00 Strike: $2.73 | $0.00 |
DisclosureSEC source: 0001104659-18-038709 · a4.xml · derivative · entry 1 Wright Karen Steil · CIK 0001310280 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,854 Underlying: Common Stock · 85,854 shares Expires 2028-04-12 F1 · security: Granted pursuant to the Issuer's 2014 Equity Incentive Plan F2 · security: All share numbers and the exercise price reflect the 1-for-15 reverse stock split effected on June 1, 2018. F3 · date: The option grant was approved by the Issuer's board of directors on April 12, 2018, subject to the stockholders approving and effecting a reverse stock split. The Issuer's shareholders approved the reverse stock split on May 18, 2018 and effected such stock split on June 1, 2018. F4 · derivative.exercise_date: Vests in equal monthly installments, beginning on May 1, 2018, such that it is vested in full on the 3-year anniversary of the grant date. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 17:32 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantStock Option (right to buy) · Derivative | 998,857 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001104659-18-017523 · a4.xml · derivative · entry 1 Wright Karen Steil · CIK 0001310280 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 998,857 Underlying: Common Stock · 998,857 shares Expires 2027-08-02 F1 · security: Granted pursuant to the Issuer's 2014 Stock Incentive Plan. F2 · date: The option grant was approved by the Issuer's board of directors on August 2, 2017, subject to shareholder approval of the amendment to the 2014 Stock Incentive Plan. The Issuer's shareholders approved the amendment on March 12, 2018. F3 · derivative.exercise_date: Vests in equal monthly installments, beginning August 2, 2017, such that it is vested in full on the 3-year anniversary of the grant date. Read SEC document |
| December 21, 2017 Filed Dec 29, 2017 17:26 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantStock Option (right to buy) · Derivative | 54,295 | $0.00 Strike: $0.12 | $0.00 |
DisclosureSEC source: 0001104659-17-075721 · a4.xml · derivative · entry 1 Wright Karen Steil · CIK 0001310280 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,295 Underlying: Common Stock · 54,295 shares Expires 2027-12-21 F1 · security: Granted pursuant to the Issuer's 2014 Equity Incentive Plan F2 · derivative.exercise_date: Vests in full on March 31, 2018 if reporting person is an employee as of such date. Read SEC document |
| December 19, 2016 Filed Dec 21, 2016 14:38 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantStock Option (right to buy) · Derivative | 2,866 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0001104659-16-163179 · a4.xml · derivative · entry 1 Wright Karen Steil · CIK 0001310280 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,866 Underlying: Common Stock · 2,866 shares Expires 2026-12-19 F1 · security: Granted pursuant to the Issuer's 2014 Equity Incentive Plan F2 · derivative.exercise_date: Vests in equal monthly installments, beginning on January 19, 2017, such that it is vested in full on the 3-year anniversary of the grant date. Read SEC document |
| September 22, 2016 Filed Sep 23, 2016 15:00 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantStock Option (right to buy) · Derivative | 103,698 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0001104659-16-146280 · a4.xml · derivative · entry 1 Wright Karen Steil · CIK 0001310280 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,698 Underlying: Common Stock · 103,698 shares Expires 2026-09-22 F1 · security: Granted pursuant to the Issuer's 2014 Equity Incentive Plan F2 · derivative.exercise_date: Vests in equal monthly installments, beginning on October 22, 2016, such that it is vested in full on the 3-year anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.